Already on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the ...
Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...
Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback